版本:
中国

BRIEF-U.S. FDA Division of Hematology products lifts partial clinical hold on Selinexor clinical trials

March 30 Karyopharm Therapeutics Inc

* U.S. FDA Division of Hematology products lifts partial clinical hold on Karyopharm’S Selinexor clinical trials

* Timelines for ongoing and planned studies expected to remain materially unchanged

* Recruitment resumes across all Selinexor trials in hematological malignancies

* Investigator sponsored trials in hematologic malignancies with Selinexor may resume accruing patients Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐